Testing imdusiran for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had hepatitis B for more than 6 months and still test positive for HBsAg (a hepatitis B marker).
- You have been taking an oral antiviral medicine for hepatitis B for at least 6 months and are willing to stay on it.
- Your hepatitis B virus level is very low (undetectable or almost undetectable) for 6 months or more.
- You do not have cirrhosis (severe liver scarring) or other serious liver conditions.
- You do not have HIV, hepatitis C (unless treated), or hepatitis D.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.